Sarcoidosis – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026
Sarcoidosis Emerging Therapy and TPP Insights Thelansis’s “Sarcoidosis Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Sarcoidosis Overview Sarcoidosis is a multisystem granulomatous disorder of incompletely understood aetiology, characterised by the pathological accumulation of non-caseating granulomas — composed of activated macrophages, epithelioid cells, and CD4+ T-lymphocytes — in affected organs, driven by dysregulated innate and adaptive immune responses to unidentified antigenic triggers in genetically susceptible individuals. The lungs and intrathoracic lymph nodes are involved in over 90% of cases, with frequent additional involvement of skin, eyes, liver, spleen, heart, and nervous system. Patients present heterogeneously — r...